Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
27 juil. 2023 08h00 HE
|
Avalyn Pharma Inc.
SEATTLE , July 27, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
15 juin 2023 08h00 HE
|
Avalyn Pharma Inc.
SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
23 mai 2023 08h00 HE
|
Avalyn Pharma Inc.
SEATTLE, May 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today presented...
Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
11 mai 2023 08h00 HE
|
Avalyn Pharma Inc.
- Avalyn CEO to Present in Company Showcase and Moderate Panel Discussion at ATS RIS - - Results from Long-Term Treatment of Pulmonary Fibrosis with AP01 to be Presented at ATS - SEATTLE, May 11,...
Avalyn Pharma Presenting at BioEquity Europe
10 mai 2023 07h30 HE
|
Avalyn Pharma Inc.
Seattle, WA, May 10, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today...
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis
11 avr. 2023 08h00 HE
|
Avalyn Pharma Inc.
Seattle, April 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today reported...
Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
30 mars 2023 08h00 HE
|
Avalyn Pharma Inc.
Seattle, March 30, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today...
Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
23 mars 2023 13h23 HE
|
Avalyn Pharma Inc.
SEATTLE , March 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
28 nov. 2022 12h00 HE
|
Avalyn Pharma Inc.
SEATTLE , Nov. 28, 2022 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...